Navigation Links
Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
Date:11/18/2010

g, including statements related to future preclinical and clinical development plans for its product candidates. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause Oncothyreon's actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, the safety and efficacy of Oncothyreon's product candidates, and the indications for which Oncothyreon's product candidates might be developed. There can be no guarantee that the results of preclinical studies or clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Oncothyreon Reports Third Quarter 2010 Financial Results
2. Oncothyreon to Present at JMP Securities Healthcare Conference
3. ONCOTHYREON ANNOUNCES PRICING OF $14.9 MILLION PRIVATE PLACEMENT
4. ONCOTHYREON APPOINTS JULIE M. EASTLAND AS CHIEF FINANCIAL OFFICER
5. Oncothyreon reports second quarter 2010 financial results
6. Oncothyreon announces second quarter 2010 financial results conference call
7. Oncothyreon announces presentations at upcoming investor conferences in June
8. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
9. Oncothyreon reports full year and fourth quarter 2009 financial results
10. Oncothyreon reports first quarter 2010 financial results
11. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Involution ... the release of a new infographic, Understanding Ebola ... create a beautifully designed, easy to follow informative tool ... areas of outbreak, symptoms and prevention. , "As the ... that the 2014 Ebola outbreak represents not only a ...
(Date:10/22/2014)... 2014 Grace Century, a private equity ... announces the addition of Dr. Yousef “Josh” Siddiqui ... team. Dr. Siddiqui will provide further healthcare expertise to ... of University College Medical School in the ... in 2001. With further certification as a General Practitioner ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... LAUSANNE, Switzerland, April 11 Galderma Pharma ... dermatology, today,announced that its U.S. holding company, ... CollaGenex Pharmaceuticals, Inc. (Nasdaq:,CGPI). As a result ... wholly owned,subsidiary of Galderma Laboratories., "We ...
... (http://www.spectodesign.com ), a leading Los Angeles branding and ... renowned biomedical research,institute. (http://www.liai.org ), "This ... the content to the user with,high-impact visuals and user-centric ... for Allergy & Immunology,s dedication to,Finding Cures Faster, in ...
... Inc. (Nasdaq: PPHM ), a clinical stage ... cancer and,hepatitis C virus infection (HCV), today announced ... of oral and poster presentations,at the 2008 Annual ... being held April 12-16, 2008 in San Diego:, ...
Cached Biology Technology:Galderma Completes Acquisition of CollaGenex 2Galderma Completes Acquisition of CollaGenex 3Galderma Completes Acquisition of CollaGenex 4La Jolla Institute for Allergy & Immunology Wows With New Website 2Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting 2
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... Scientists now understand how an important protein converts chemical ... cell division, thanks to a new structural model by ... , The structural model helps solve a scientific mystery: ... functions vital to life. These functions include mitosis, or ...
... the first large, single-institution series directly comparing weight-loss ... of Chicago found that a newer operation, the ... the standard operation, the Roux-en-Y gastric bypass. , ... Surgery, the researchers report that the duodenal switch ...
... public alike have been acutely aware of the potential ravages ... might still recall the pandemics of 1968 and 1957, it ... on that scale--that causes the most trepidation. ... died from this particular strain of the flu virus in ...
Cached Biology News:UNC scientists solve mystery of how largest cellular motor protein powers movement 2For super-obese patients, duodenal switch beats gastric bypass 2For super-obese patients, duodenal switch beats gastric bypass 3Recurrence of a flu pandemic similar to infamous 1918 flu could kill 62 million 2Recurrence of a flu pandemic similar to infamous 1918 flu could kill 62 million 3
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
... Mung Bean Nuclease catalyzes the degradation ... yield 5-phosphoryl terminated products. While the nuclease ... very high concentrations the enzyme degrades double-stranded ... Nuclease has been used for transcript mapping ...
Biology Products: